(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...

In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an ...

Ozempic is linked to a potentially higher risk of vision loss in some studies. Doctors explain how GLP-1 drugs for diabetes ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased ...

This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition. Last month, the European Medicines ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare eye condition known as NAION (non-arteritic anterior ischemic optic ...

The long-term implications of repeated injection-associated IOP elevations are under investigation. Our study analyzes the optic nerve by looking at 2 key metrics: Bruch membrane to anterior lamina ...